300482.SZ
万孚生物
SZSE · Healthcare · C 制造业 · CN
CNY 16.00
−8.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.9B | 2.1B | 3.1B | 2.8B | 5.7B |
| Cost of Revenue | 845.0M | 897.9M | 1.1B | 1.0B | 2.7B |
| Gross Profit | 1.0B | 1.2B | 2.0B | 1.7B | 2.9B |
| Operating Expenses | |||||
| R&D Expense | 307.2M | 336.7M | 411.5M | 378.0M | 418.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 287.4M | 299.4M | 222.4M | 227.1M | 227.9M |
| Selling & Marketing Expense | 637.3M | 658.8M | 683.5M | 650.0M | 929.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.3B | 1.4B | 1.3B | 1.3B | 1.6B |
| Cost and Expenses | 2.2B | 2.2B | 2.4B | 2.3B | 4.3B |
| Operating Income (EBIT) | (228.1M) | (110.4M) | 636.8M | 549.1M | 1.4B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (232.5M) | (114.7M) | 629.5M | 540.8M | 1.4B |
| Income Tax Expense | (58.9M) | (45.0M) | 64.2M | 53.3M | 174.4M |
| Bottom Line | |||||
| Net Income | (167.8M) | (63.0M) | 561.6M | 487.6M | 1.2B |
| Earnings from Cont. Ops | (173.5M) | (69.6M) | 565.2M | 491.0M | 1.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (167.8M) | (63.0M) | 561.6M | 487.6M | 1.2B |
| Per Share | |||||
| Basic EPS | (CN¥0.34) | (CN¥0.13) | CN¥1.21 | CN¥1.10 | CN¥2.71 |
| Diluted EPS | (CN¥0.34) | (CN¥0.13) | CN¥1.21 | CN¥1.10 | CN¥2.71 |
| Revenue Per Share | CN¥3.98 | CN¥4.30 | CN¥6.60 | CN¥6.24 | CN¥12.86 |
| Shares | |||||
| Basic Shares Outstanding | 468.9M | 484.8M | 464.2M | 443.3M | 441.7M |
| Diluted Shares Outstanding | 468.9M | 484.8M | 464.2M | 443.3M | 441.7M |
| Profitability Metrics | |||||
| EBITDA | — | 152.6M | 890.5M | 806.2M | 1.6B |
| D&A | — | 263.0M | 253.7M | 257.1M | 251.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026